Amoun

Executive Summary

Amoun, a private pharmaceutical company headquartered in Cairo, has been operating since 1998, focusing on the production of antibiotics, cardiovascular drugs, and gastrointestinal treatments for markets in Africa and the Middle East. With a workforce of 200–500 employees, the company has built a solid reputation for supplying essential medicines to underserved regions. Its extensive product portfolio and established distribution network position it as a key player in the regional generics market. Despite the lack of recent public disclosures or pipeline updates, Amoun’s long-standing presence and commercial stage suggest steady revenue generation from existing products. Growth potential lies in expanding its geographic footprint and introducing new generic formulations to address local health priorities.

Upcoming Catalysts (preview)

• Q3 2026Market expansion into sub-Saharan Africa70% success
• Q2 2026Launch of a new generic cardiovascular drug80% success
• TBDStrategic manufacturing partnership for regional supply60% success